Allied-Bristol Life Sciences, LLC, a biopharmaceutical enterprise
jointly owned between Allied Minds (LSE: ALM) and Bristol-Myers Squibb
Company (NYSE: BMY), today announced that it formed a strategic
partnership with Synergy Partners R&D Solutions, LLC.
Synergy Partners, co-founded by Catherine D. Strader, Ph.D. and James S.
MacDonald, Ph.D., comprises a network of over 20 well-respected experts
that collectively have taken more than 100 drugs from discovery through
development. Their team of scientists offers expertise in areas such as
disease biology, medicinal chemistry, process chemistry, toxicology,
pharmacology and drug safety, and have proven track records at many of
the world’s leading biopharmaceutical companies, including Bristol-Myers
Squibb, Merck & Co., AstraZeneca, Pfizer Inc., Johnson & Johnson and Eli
Lilly & Co.
This collective expertise offers essential insights for Allied-Bristol
Life Sciences’ efforts to identify the most promising early-stage
therapeutic opportunities at leading U.S. academic research
institutions, and transform them into robust pre-clinical candidates for
follow-on clinical development.
“The drug development team at Synergy Partners includes leaders within
the biopharmaceutical industry in diseases of high interest to
Allied-Bristol Life Sciences. We are pleased to have them joining our
team as we move forward with this unique opportunity to advance academic
innovations to drug candidates,” said Chris Silva, Chief Executive
Officer of Allied Minds.
Allied-Bristol Life Sciences was formed earlier this year to identify
discoveries from academic labs with promising therapeutic and commercial
potential, and to drive these early-stage innovations from initial
feasibility to pre-clinical candidacy. Synergy Partners will assist
these efforts by lending strategic insights and decades of experience in
the development, execution and management of critical experiments and
achievement of key milestones needed to successfully advance each
research program.
“We are excited by the opportunity to work with Allied-Bristol
Life Sciences to build a portfolio of novel and
differentiated pre-clinical candidates,” said Synergy Partners’ Strader.
“Synergy Partners is committed to bringing innovative new medicines to
patients and Allied-Bristol Life Sciences offers a terrific model for
optimizing innovation in the world of biopharmaceuticals.”
About Allied-Bristol Life Sciences
Allied-Bristol Life Sciences (ABLS) is a joint venture between Allied
Minds and Bristol-Myers Squibb Co. that aims to deliver the important
medicines for tomorrow. Based upon compelling biological discoveries and
insights from scientists at leading U.S. research institutions, ABLS
will identify, source and de-risk promising, early-stage therapeutic
opportunities, from discovery through development, in key therapeutic
areas, including fibrosis, cardiovascular diseases, oncology,
immunology, virology and genetically defined diseases. For more
information, visit http://alliedminds.com/subsidiaries/allied-bristol.
About Allied Minds
Allied Minds (LSE: ALM) is an innovative U.S. science and technology
development and commercialization company. Operating since 2006, Allied
Minds forms, funds, manages and builds products and businesses based on
innovative technologies developed at leading U.S. universities and
federal research institutions. Allied Minds serves as a diversified
holding company that supports its businesses and product
development with capital, central management and shared services. More
information about the Boston-based company can be found at www.alliedminds.com.
Allied Minds Forward-Looking Statement
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company’s future prospects, developments and strategies. The
forward-looking statements are based on current expectations and are
subject to known and unknown risks and uncertainties that could cause
actual results, performance and achievements to differ materially from
current expectations, including, but not limited to, those risk and
uncertainties described in the risk factors included in the company’s
regulatory filings. These forward-looking statements are based on
assumptions regarding the present and future business strategies of the
company and the environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press
release. Except as required by law, regulatory requirement, the
Prospectus Rules, the Listing Rules and the Disclosure and Transparency
Rules, neither the company nor any other party intends to update or
revise these forward-looking statements, whether as a result of new
information, future events or otherwise.
Copyright Business Wire 2014